R&D Department, Inclinica, Wayne, Pennsylvania, USA.
Department of Ophthalmology and Visual Sciences of the Federal University of São Paulo, , São Paulo, Brazil.
Ocul Immunol Inflamm. 2020;28(2):249-255. doi: 10.1080/09273948.2019.1569242. Epub 2019 Feb 26.
: To evaluate the effectiveness of treatments for ocular toxoplasmosis (OT).: A review of charts was conducted from patients who experienced an active episode of OT treated at the Federal University of São Paulo and associated sites. OT charts were reviewed to determine treatment effectiveness based on clinical judgment, taking clinical course and outcome into consideration in addition to change in best-corrected visual acuity. Treatment emergent adverse events (TEAEs) were used to assess safety.: Overall, 451/1200 patient charts met the inclusion criteria. The most commonly prescribed treatment was trimethoprim + sulfamethoxazole (52.3%) followed by pyrimethamine + sulfadiazine (28%). Treatment was successful in 96.9% of patients. Irrespective of the treatment, active lesions were resolved in 63.9% of patients within 6 weeks. Vision improved in 56.3% of patients. The incidence of TEAEs was low (10%).: All treatments were effective for active episodes of OT, with few side effects.
评估眼部弓形体病(OT)治疗效果。对在圣保罗联邦大学及其附属医院接受治疗的活跃期 OT 患者的病历进行了回顾性分析。根据临床判断、临床病程和结果以及最佳矫正视力的变化来确定治疗效果,同时考虑了这些因素。治疗中出现的不良事件(TEAEs)用于评估安全性。
总体而言,有 451/1200 份患者病历符合纳入标准。最常开的治疗药物是复方磺胺甲噁唑(52.3%),其次是乙胺嘧啶+磺胺嘧啶(28%)。96.9%的患者治疗成功。无论治疗方式如何,63.9%的患者在 6 周内活动性病变得到解决。56.3%的患者视力有所改善。TEAEs 的发生率较低(10%)。
所有治疗方法对 OT 的活跃期均有效,副作用较少。